{"slideshow_credits": null, "snippet": "Interferon beta, the most commonly prescribed drug to treat M.S., helps reduce the development of brain lesions and limit the frequency of relapses.", "abstract": "University of British Columbia study finds interferon beta, the most widely prescribed drug for treating multiple sclerosis, has little or no effect on a patient's progression to disability; finds it does help reduce the development of brain lesions and limit the frequency of relapses.", "section_name": "Health", "print_page": "14", "document_type": "article", "byline": {"person": [{"firstname": "Nicholas", "role": "reported", "lastname": "BAKALAR", "rank": 1, "organization": ""}], "original": "By NICHOLAS BAKALAR", "contributor": ""}, "web_url": "http://www.nytimes.com/2012/07/18/health/research/multiple-sclerosis-drug-doesnt-stop-disability-study-finds.html", "lead_paragraph": "Interferon beta, the most commonly prescribed drug to treat M.S., helps reduce the development of brain lesions and limit the frequency of relapses.", "headline": {"seo": "Multiple Sclerosis Drug Doesn\u2019t Stop Disability, Study Finds", "main": "Multiple Sclerosis Drug Doesn\u2019t Prevent Onset of Disability, Study Finds", "print_headline": "Multiple Sclerosis Drug Doesn\u2019t Prevent Onset of Disability, Study Finds"}, "_id": "53f8e7cc38f0d84410bca8c9", "word_count": "580", "multimedia": [], "pub_date": "2012-07-18T00:00:00Z", "source": "The New York Times", "news_desk": "National", "keywords": [{"value": "Multiple Sclerosis", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "University of British Columbia", "name": "organizations", "is_major": "N", "rank": "2"}, {"value": "Journal of the American Medical Assn", "name": "organizations", "is_major": "N", "rank": "3"}, {"value": "Interferon Beta (Drugs)", "name": "subject", "is_major": "Y", "rank": "4"}], "blog": [], "subsection_name": "Research", "type_of_material": "News"}